4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Melanoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 2308 ongoing clinical trials involving Melanoma
Of the 2308 trials,687 trials are in Phase I/II
Furthermore, 576 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Melanoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Melanoma, an Oncology condition. The largest number of ongoing clinical trials for Melanoma is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Melanoma-related drug trials.

University of Texas MD Anderson Cancer Center: The leading ongoing Melanoma related clinical trial sponsor

University of Texas MD Anderson Cancer Center is the top sponsor for Melanoma-related ongoing clinical trials.

National Cancer Institute US, Bristol-Myers Squibb Co, Novartis AG, Merck & Co Inc, and University of Pittsburgh are among other notable clinical trial sponsors involved in Melanoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Melanoma

Pembrolizumab (Keytruda), Nivolumab (Opdivo, Opdyta), and Atezolizumab (Tecentriq) are among the key marketed drugs involving Melanoma.

Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Keytruda is formulated as lyophilized powder for solution, solution concentrate for intravenous route of administration. Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor. Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Pembrolizumab was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Merck Sharp & Dohme Corp.

Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal antibody. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Opdivo is formulated as solution and concentrate solution for intravenous route of administration. Nivolumab is indicated for the treatment of unresectable melanoma. Opdivo as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation was positive, a BRAF inhibitor. Nivolumab was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Bristol-Myers Squibb Co.